TREATMENT FOR CENTRAL-INVOLVED DIABETIC MACULAR EDEMA IN EYES WITH VERY GOOD VISUAL ACUITY

Registry ID

DRCR.NET

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC

Start date

2014-06-20

Last update

2014-06-12

Conditions

• MACULAR EDEMA

Related clinical trials

• A PHASE III, MULTI¿CENTER, RANDOMIZED, DOUBLE¿MASKED, SHAM¿CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 ADMINISTERED INTRAVITREALLY IN PATIENTS WITH UVEITIC MACULAR EDEMA
• AN EIGHTEEN-MONTH, TWO-ARM, RANDOMIZED, DOUBLE-MASKED, MULTICENTER, PHASE III STUDY ASSESSING THE EFFICACY AND SAFETY OF BROLUCIZUMAB VERSUS AFLIBERCEPT IN ADULT PATIENTS WITH VISUAL IMPAIRMENT DUE TO MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION (RAVEN)
• AN EIGHTEEN-MONTH, TWO-ARM, RANDOMIZED, DOUBLE-MASKED, MULTI-CENTER, PHASE III STUDY ASSESSING THE EFFICACY AND SAFETY OF BROLUCIZUMAB VERSUS AFLIBERCEPT IN ADULT PATIENTS WITH VISUAL IMPAIRMENT DUE TO MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION (RAPTOR)
• A 12-MONTH, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 0.5MG RANIBIZUMAB INTRAVITREAL INJECTIONS IN PATIENTS WITH VISUAL IMPAIRMENT DUE TO VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) DRIVEN MACULAR EDEMA (ME).

View on source registry